ID

22831

Descrição

Fulvestrant in Hormone Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00476645

Link

https://clinicaltrials.gov/show/NCT00476645

Palavras-chave

Versões (1)
  1. 12/06/2017 12/06/2017 -
Transferido a

12 de junho de 2017

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Prostatic Neoplasms NCT00476645

Inglês

Eligibility Prostatic Neoplasms NCT00476645

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
must give signed written informed consent
Descrição

Informed Consent

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0021430
must be of age 18 years or older
Descrição

Age

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001779
histologically confirmed adenocarcinoma of the prostate
Descrição

Adenocarcinoma of prostate

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0007112
must be currently receiving lhrh agonists and have castrate levels of testosterone or have had an orchiectomy
Descrição

Luteinizing Hormone-releasing Hormone Agonist | Testosterone measurement | Orchiectomy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1518041
UMLS CUI [2]
C0523912
UMLS CUI [3]
C0029189
must have had rise in psa despite anti-androgen withdrawal
Descrição

Raised prostate specific antigen | Androgen Antagonists Withdrawal

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0178415
UMLS CUI [2,1]
C0002842
UMLS CUI [2,2]
C2349954
must exhibit two consecutive rises in psa after the last hormonal manipulation
Descrição

Raised prostate specific antigen Quantity Post Hormone Therapy

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0178415
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0687676
UMLS CUI [1,4]
C0279025
minimum psa > 5mg/dl
Descrição

Prostate-Specific Antigen Minimum

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0138741
UMLS CUI [1,2]
C1524031
kps > 80%
Descrição

Karnofsky Performance Status

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0206065
up to one prior chemotherapy treatments allowed
Descrição

Chemotherapy Quantity

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C1265611
life expectancy of greater than 6 months
Descrição

Life Expectancy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0023671
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
concomitant hormonal therapy other than an lhrh
Descrição

Hormone Therapy | LHRH

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0279025
UMLS CUI [2]
C0023610
noncompliance
Descrição

Non-compliance

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0457432
platelets less than 100 x 10e9 /l
Descrição

Platelet Count measurement

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0032181
international normalization ratio (inr) greater than 1.6
Descrição

International Normalized Ratio

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0525032
total bilirubin greater than 1.5 x ulrr
Descrição

Elevated total bilirubin

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0741494
alt or ast greater than 2.5 x ulrr if no demonstrable liver metastases or greater than 5.0 x ulrr in presence of liver metastases
Descrição

Alanine aminotransferase increased | Aspartate aminotransferase increased | Secondary malignant neoplasm of liver

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0151905
UMLS CUI [2]
C0151904
UMLS CUI [3]
C0494165
history of bleeding diathesis (ie, disseminated intravascular coagulation [dic], clotting factor deficiency)
Descrição

Bleeding tendency | Disseminated Intravascular Coagulation | Clotting factor deficiency

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1458140
UMLS CUI [2]
C0012739
UMLS CUI [3]
C0272315
history of long-term anticoagulant therapy (other than antiplatelet therapy)
Descrição

Anticoagulant therapy Long-term | Antiplatelet therapy

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0150457
UMLS CUI [1,2]
C0443252
UMLS CUI [2]
C1096021
history of hypersensitivity to active or inactive excipients of fulvestrant (ie, castor oil or mannitol)
Descrição

Hypersensitivity Fulvestrant Excipient | Hypersensitivity Fulvestrant inactive ingredient | Castor oil allergy | Mannitol allergy

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0935916
UMLS CUI [1,3]
C0015237
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0935916
UMLS CUI [2,3]
C1552019
UMLS CUI [3]
C0571232
UMLS CUI [4]
C0571922
Voltar ao início da página

Similar models

Eligibility Prostatic Neoplasms NCT00476645

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
must give signed written informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
must be of age 18 years or older
boolean
C0001779 (UMLS CUI [1])
Adenocarcinoma of prostate
Item
histologically confirmed adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Luteinizing Hormone-releasing Hormone Agonist | Testosterone measurement | Orchiectomy
Item
must be currently receiving lhrh agonists and have castrate levels of testosterone or have had an orchiectomy
boolean
C1518041 (UMLS CUI [1])
C0523912 (UMLS CUI [2])
C0029189 (UMLS CUI [3])
Raised prostate specific antigen | Androgen Antagonists Withdrawal
Item
must have had rise in psa despite anti-androgen withdrawal
boolean
C0178415 (UMLS CUI [1])
C0002842 (UMLS CUI [2,1])
C2349954 (UMLS CUI [2,2])
Raised prostate specific antigen Quantity Post Hormone Therapy
Item
must exhibit two consecutive rises in psa after the last hormonal manipulation
boolean
C0178415 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0687676 (UMLS CUI [1,3])
C0279025 (UMLS CUI [1,4])
Prostate-Specific Antigen Minimum
Item
minimum psa > 5mg/dl
boolean
C0138741 (UMLS CUI [1,1])
C1524031 (UMLS CUI [1,2])
Karnofsky Performance Status
Item
kps > 80%
boolean
C0206065 (UMLS CUI [1])
Chemotherapy Quantity
Item
up to one prior chemotherapy treatments allowed
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Life Expectancy
Item
life expectancy of greater than 6 months
boolean
C0023671 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Hormone Therapy | LHRH
Item
concomitant hormonal therapy other than an lhrh
boolean
C0279025 (UMLS CUI [1])
C0023610 (UMLS CUI [2])
Non-compliance
Item
noncompliance
boolean
C0457432 (UMLS CUI [1])
Platelet Count measurement
Item
platelets less than 100 x 10e9 /l
boolean
C0032181 (UMLS CUI [1])
International Normalized Ratio
Item
international normalization ratio (inr) greater than 1.6
boolean
C0525032 (UMLS CUI [1])
Elevated total bilirubin
Item
total bilirubin greater than 1.5 x ulrr
boolean
C0741494 (UMLS CUI [1])
Alanine aminotransferase increased | Aspartate aminotransferase increased | Secondary malignant neoplasm of liver
Item
alt or ast greater than 2.5 x ulrr if no demonstrable liver metastases or greater than 5.0 x ulrr in presence of liver metastases
boolean
C0151905 (UMLS CUI [1])
C0151904 (UMLS CUI [2])
C0494165 (UMLS CUI [3])
Bleeding tendency | Disseminated Intravascular Coagulation | Clotting factor deficiency
Item
history of bleeding diathesis (ie, disseminated intravascular coagulation [dic], clotting factor deficiency)
boolean
C1458140 (UMLS CUI [1])
C0012739 (UMLS CUI [2])
C0272315 (UMLS CUI [3])
Anticoagulant therapy Long-term | Antiplatelet therapy
Item
history of long-term anticoagulant therapy (other than antiplatelet therapy)
boolean
C0150457 (UMLS CUI [1,1])
C0443252 (UMLS CUI [1,2])
C1096021 (UMLS CUI [2])
Hypersensitivity Fulvestrant Excipient | Hypersensitivity Fulvestrant inactive ingredient | Castor oil allergy | Mannitol allergy
Item
history of hypersensitivity to active or inactive excipients of fulvestrant (ie, castor oil or mannitol)
boolean
C0020517 (UMLS CUI [1,1])
C0935916 (UMLS CUI [1,2])
C0015237 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0935916 (UMLS CUI [2,2])
C1552019 (UMLS CUI [2,3])
C0571232 (UMLS CUI [3])
C0571922 (UMLS CUI [4])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial